AUSTIN, Texas (March 7 2016)—AffloVest's maker, International Biophysics Corporation, is joining the new American revolution by bringing the manufacturing of one of its main products home to this country. AffloVest is the first completely self-contained, battery operated, portable High Frequency Chest Wall Oscillation (HFCWO) device that provides critical therapy for people with cystic fibrosis, bronchiectasis and other respiratory diseases.

For U.S. companies, in the past, manufacturing off-shore made sense and cents due to low wages, tax advantages and other cost savings. But recently, the "here vs. there" differential has been leveling. Quoting H. David Shockley, Jr., International Biophysics's CEO, "We manufactured the AffloVest in Germany, but overall costs in Europe, like China, kept rising."

That “Made in the U.S.A.” brand offered International Biophysics, like others, some of the highest productivity and quality levels in the world. “By on-shoring our manufacturing we are creating great jobs domestically, made possible by improved quality and cost competitiveness. We all win." Shockley added.

International Biophysics's new "Made in America" product features several innovations from its previous design including a better overall tailored fit, a more fashionable denim color, an electronic digital, programmable controller with compliance monitoring, longer battery life and more sizes. International Biophysics is also introducing the new AffloVest Pro, a special infection control enhanced hospital version, which is disposable and gives health care professionals greater oscillation control to target specific parts of the lungs.

Independent clinical studies of the AffloVest document that its users experience improved lung function, attributed to the AffloVest's patent pending motor-driven, directed oscillation therapy and to its portability and ease of use, which increases patient compliance.

An independent study was conducted by Michael Cooper, a registered respiratory therapist at one of the leading pediatric respiratory care clinics in the country. Cooper found "improved FEV 1, FEF and FVC Ratios for all the patients together was over 10 percent. With the AffloVest, the direct percussion as well as the vibration, with that combo, it's a win-win."

Visit for more information.